Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) had its price target lowered by analysts at Wells Fargo & Company from $11.00 to $10.00. They now have an "equal weight" rating on the stock.
Monte Rosa Therapeutics, Inc. (GLUE)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
GLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLUE alerts
High impacting Monte Rosa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GLUE
News
- Mixed data results for two Monte Rosa molecular glue degraders [Yahoo! Finance]Yahoo! Finance
- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $17.00 price target on the stock, up previously from $15.00.MarketBeat
- Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 ProgramsGlobeNewswire
- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $19.00 price target on the stock.MarketBeat
- Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025GlobeNewswire
GLUE
Earnings
- 8/8/24 - Beat
GLUE
Sec Filings
- 3/25/25 - Form 4
- 3/20/25 - Form S-3
- 3/20/25 - Form S-8
- GLUE's page on the SEC website